.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Teva
Fuji
Johnson and Johnson
Harvard Business School
Healthtrust
McKinsey
Baxter
Argus Health
Chubb

Generated: July 23, 2017

DrugPatentWatch Database Preview

ACCOLATE Drug Profile

« Back to Dashboard

What is the patent landscape for Accolate, and what generic Accolate alternatives are available?

Accolate is a drug marketed by Par Pharm Inc and is included in one NDA.

The generic ingredient in ACCOLATE is zafirlukast. There are two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the zafirlukast profile page.

Summary for Tradename: ACCOLATE

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list67
Clinical Trials: see list1
Patent Applications: see list4,226
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ACCOLATE at DailyMed

Pharmacology for Tradename: ACCOLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 1999ABRXYesNo► Subscribe► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-001Sep 26, 1996ABRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ACCOLATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-001Sep 26, 19965,583,152► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 19995,583,152► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 19995,612,367► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 19994,859,692► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 19996,143,775► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ACCOLATE

Drugname Dosage Strength RLD Submissiondate
zafirlukastTablets10 mg and 20 mgAccolate2/29/2008
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Merck
Johnson and Johnson
Covington
Deloitte
US Department of Justice
Medtronic
Express Scripts
Argus Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot